

Reference: FOI.ICB-2526/120

Subject: NICE Technology Appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro)

I can confirm that the ICB does hold the information requested; please see responses below:

QUESTION	RESPONSE
1. What was your financial allocation for 2025/2026 to support the Implementation of the NICE Technology Appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro) for the management of obesity?	Funding allocation for BNSSG is in two different components: £246,000 - medicine £149,000 - primary care management
2. How many patients does this financial allocation support treatment of in 2025/2026?	NHS England (NHSE) have calculated this on the basis of ICB-level obesity prevalence and based on the following assumptions: Based on the eligibility criteria, there are an estimated 32,000 patients expected to be receiving treatment in 25/26. This has been allocated to each ICB using a weighted population split using obesity prevalence. It is expected that approximately 70% of those assessed will proceed with treatment. The calculations also take account of the titration process before patients continue at a maintenance dose. It is assumed that 5% of patients drop out every 6 months. NHSE predicted patient cohort (70% of patient inflow) for BNSSG = 343.

3. How many patients have you identified as being eligible in year 1?	Local modelling using EMIS data suggests 1272 eligible patients in year 1. Excluding those already with a current GLP-1/GIP gave 877. Applying 70% of patient inflow estimates 613 patients will be treated in year 1.
4. If there is a shortfall in funding compared to expected eligibility, how do you anticipate funding this treatment shortfall?	Yes, the ICB has identified a potential risk/deficit, and this will be funded locally.
5. Have you started prescribing Mounjaro in line with this NICE funding variation? If not, when will you start?	Yes, prescribing of Mounjaro in line with the NICE funding variation is being rolled out in primary care.
6. What model of care will you use for its delivery?	The ICB is currently using a General Practice primary care model (supported by LES) with face-to-face appointments at initiation, 6 months and 12 months, patient contact at weeks 4,8,12 and 16 and wraparound care as per nationally arranged service.

The information provided in this response is accurate as of 24 July 2025 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.